Why is $CRSP moving today? · SEC 8-K archive

$CRSP SEC Filing Alert & Real-Time AI Stock Impact Analysis

T0 SEO archive for $CRSP: filings appear instantly. AI score, direction and bullet analysis unlock publicly after 4 hours (VIP sees them live).

← All archive signals

FAQ: $CRSP filing catalyst

Why did $CRSP trigger an AI stock catalyst alert?

$CRSP triggered a Stock Catalyst AI alert on 2026-11-02 00:00:00 UTC for a SEC 8-K filing (AI Score: +3.0/10). Headline: CRISPR Therapeutics Reports Q3: CASGEVY Sales Reach $99M (+30% QoQ), Net Loss $111.4M. Key points: - CASGEVY Q3 revenue was $99 million, up 30% QoQ and ~6x year-over-year with >750 patients treated. - Q3 net loss widened slightly to $111.4 million compared to $106.4 million in Q3 2025; GAAP EPS reported at $(1.15). - G&A expenses held stable at $17.9 million versus $16.9 million in the prior-year period.

How did $CRSP stock react after the SEC filing?

After the SEC 8-K for $CRSP, observed market reaction: T0 price $49.99. Past moves do not guarantee future results.

Where can I get real-time $CRSP SEC filing alerts?

Stock Catalyst AI pushes real-time SEC 8-K alerts for $CRSP via Telegram and the VIP Web Terminal from €10/month.

$CRSP

$CRSP – CRISPR Therapeutics Reports Q3: CASGEVY Sales Reach $99M (+30% QoQ), Net Loss $111.4M

CRISPR Therapeutics AG

2026-11-02 00:00:00 UTC · SEC 8-K · All $CRSP

Unlocked archive · Analyzed in <2s at T0

Bullish AI Sentiment (+3.0 / 10)

CASGEVY Q3 revenue was $99 million, up 30% QoQ and ~6x year-over-year with >750 patients treated.
Q3 net loss widened slightly to $111.4 million compared to $106.4 million in Q3 2025; GAAP EPS reported at $(1.15).
G&A expenses held stable at $17.9 million versus $16.9 million in the prior-year period.

Unlock Live VIP Terminal & Telegram – €10/mo Original filing →